HBM Healthcare HBMN.SW (SIX) EPS 13.66 after-hours 23 Jan 2026: valuation focus
HBMN.SW stock jumped after HBM Healthcare Investments AG reported strong earnings on 23 Jan 2026, lifting the share to CHF 244.00 in after-hours trading. The company posted EPS 13.66, a key driver of the +2.95% move from the previous close of CHF 237.00. We examine how the results affect valuation, dividend yield and investor outlook on the SIX Swiss exchange, and place the report in sector context using Meyka AI’s data-driven analysis.
Earnings snapshot and immediate market reaction
HBM Healthcare Investments AG reported results timed with the 23 Jan 2026 earnings release, and the stock traded in after-hours at CHF 244.00, up CHF 7.00 or 2.95% from the prior close. The company’s EPS of 13.66 sits alongside a P/E of 17.68, which helped traders re-rate the share after the print.
Volume stayed light at 4,092 shares versus an average of 7,945, consistent with after-hours activity. Day range showed a low of CHF 241.00 and a high of CHF 244.50, suggesting buyers stepped in on the earnings beat.
HBMN.SW stock valuation and income profile
Valuation metrics show mixed signals: price-to-book is 0.96 while P/E is 17.65, roughly in line with the Swiss Financial Services sector average P/E 16.71. HBM pays dividend per share CHF 7.50, giving a dividend yield near 3.11%, and a payout ratio of 0.36, underlining a steady income component for investors.
Book value per share stands at CHF 251.31, meaning the market price of CHF 244.00 trades slightly below net asset value. That gap frames debate between value-oriented investors and those focused on NAV growth from private portfolio exits.
Portfolio, growth signals and sector context
HBM Healthcare invests across private and public healthcare companies, with emphasis on biotech and medtech. Recent financial growth shows net income growth 18.12% and EPS growth 18.00% year-over-year, indicating improving earnings from portfolio realisations and mark-ups.
Compare this to the Swiss Healthcare sector, which has shown steady performance; HBM’s asset-management structure means sector trends in healthcare and deal activity will drive medium-term returns rather than recurring operating revenue.
Meyka AI rates HBMN.SW with a score out of 100
Meyka AI rates HBMN.SW with a score of 70.17 out of 100 (Grade: B+, Suggestion: BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade balances a near-NAV price, solid EPS, and dividend yield against liquidity constraints and NAV reliance.
Technical indicators show momentum: RSI 67.73, ADX 34.98 (strong trend) and MACD histogram positive. Short-term technicals support the post-earnings uptick, though average volume is below broader sector averages.
Meyka AI’s forecast model projects price paths
Meyka AI’s forecast model projects a monthly level of CHF 237.52 and a yearly projection of CHF 115.34. Relative to the current price of CHF 244.00, the model implies a -2.66% change at the monthly projection and a -52.73% change at the yearly projection. Forecasts are model-based projections and not guarantees.
For active investors we outline practical targets: conservative CHF 230.00, base CHF 260.00, and bullish CHF 320.00. These targets reflect NAV dynamics, possible portfolio exits, and a premium/discount swing versus book value.
Risks, catalysts and trading considerations for HBMN.SW stock
Key risks include liquidity (average volume 7,945), NAV sensitivity to private holding valuations, and concentrated event risk from single portfolio exits. Interest coverage anomalies and cash-flow ratios warrant attention despite low net debt and a tangible book value of CHF 251.31 per share.
Catalysts include successful IPOs or trade sales from the private portfolio, stronger mark-to-market gains, and continued dividend stability. Traders should watch after-hours spreads, volumes and the SIX market session for follow-through.
Final Thoughts
HBMN.SW stock reacted positively in after-hours trading on 23 Jan 2026 after an EPS beat and a reaffirmed dividend profile, lifting the price to CHF 244.00. Our analysis balances a P/E 17.68, near-NAV price with book value CHF 251.31, and a 3.11% yield against model-driven downside scenarios. Meyka AI’s forecast model projects CHF 237.52 for the month and CHF 115.34 for the year, implying short-term -2.66% and long-term -52.73% shifts vs current price; forecasts are model-based projections and not guarantees. We present price targets at CHF 230.00 (conservative), CHF 260.00 (base) and CHF 320.00 (bullish) to frame risk-reward. For investors, the earnings print reduces near-term downside but keeps focus on portfolio exits and NAV adjustments. Use position sizing and monitor SIX liquidity and upcoming company updates for timing decisions. Meyka AI provides this data-driven market analysis as an AI-powered market analysis platform, not personalised investment advice.
FAQs
What drove the after-hours move in HBMN.SW stock on 23 Jan 2026?
The after-hours rise to CHF 244.00 followed an earnings release showing EPS 13.66. Traders reacted to stronger earnings, stable dividend metrics and a P/E of 17.68, while volume remained light at 4,092 shares.
What are Meyka AI’s short and long forecasts for HBMN.SW stock?
Meyka AI’s model projects CHF 237.52 as a monthly figure and CHF 115.34 for the year. These imply short-term downside -2.66% and longer-term downside -52.73% versus CHF 244.00. Forecasts are projections, not guarantees.
How does HBMN.SW stock compare to sector peers on valuation?
HBM trades at P/E 17.65, close to the Financial Services sector average P/E 16.71, and at price-to-book 0.96, slightly below book value. That positions HBM as relatively value-oriented within its sector.
Does HBMN.SW stock pay a dividend and what is the yield?
Yes. HBM pays dividend per share CHF 7.50, giving a yield near 3.11% and a payout ratio around 0.36, supporting income-focused allocations while NAV drivers remain key.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
